Improving Pain Therapeutics
Applying unique technologies to prolong and enhance efficacy, reduce adverse effects and increase patient’s comfort.
Menu
We are a clinical stage specialty pharmaceutical company
focused on the reformulation of established therapeutics
Our proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for using opiates very often administered post-surgically.
PRF - 110
Viscous clear oil-based solution that is instilled directly into the surgical wound
Providing localized and extended post-operative analgesia. Its physical characteristics and composition are key to it being well-tolerated and its ease of use.
Market
The currently marketed non-opiate extended relief post-surgical topical products are based on a complicated formulation with either liposomes or an artificial polymer, and contain bupivacaine.
investors Relation
Nasdaq: PRFX
1.04
CHANGE: -25.71%
DAILY VOLUME: 4,987,361
LAST UPDATE: 11-21-2024 02:00
Send us a Message
